Amivantamab Plus Chemotherapy with and without Lazertinib in EGFR-mutant NSCLC Physician's Weekly, 14 Nov 2023 Bookmark 1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3 months for the amivantamab–lazer…